AxoGen Inc (AXGN)

16.40
0.40 2.40
NASDAQ : Health Care
Prev Close 16.80
Open 16.90
Day Low/High 16.25 / 16.95
52 Wk Low/High 3.26 / 7.97
Volume 424.53K
Avg Volume 211.90K
Exchange NASDAQ
Shares Outstanding 33.10M
Market Cap 560.97M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AxoGen, Inc. Reports 2017 First Quarter Financial Results

Record Q1 Revenue of $12.2 million, representing 51% growth over prior year

Commit To Purchase AxoGen At $10, Earn 12.9% Annualized Using Options

Investors considering a purchase of AxoGen Inc shares, but cautious about paying the going market price of $11.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $10 strike, which has a bid at the time of this writing of 65 cents.

Exelon, Valley National Bancorp, Skyworks Solutions: 'Mad Money' Lightning Round

Exelon, Valley National Bancorp, Skyworks Solutions: 'Mad Money' Lightning Round

Jim Cramer is bullish on Exelon and Valley National Bancorp, but he's bearish on AxoGen and SeaDrill Limited.

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

Political negatives keep popping up, forcing us to rethink the Trump trade, says Jim Cramer.

AxoGen Reaches Analyst Target Price

In recent trading, shares of AxoGen Inc have crossed above the average analyst 12-month target price of $10.31, changing hands for $10.45/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AxoGen Appoints Ivica Ducic Medical Director

AxoGen Appoints Ivica Ducic Medical Director

Peripheral Nerve Surgery Expert Brings More Than 15 Years of Clinical Experience to AxoGen

AxoGen To Participate At AAHS ASPN ASRM Joint 2017 Annual Meeting

AxoGen To Participate At AAHS ASPN ASRM Joint 2017 Annual Meeting

AxoGen to host expert panel discussion and interactive session on new nerve repair technologies

AxoGen Reaches Analyst Target Price

AxoGen Reaches Analyst Target Price

In recent trading, shares of AxoGen Inc have crossed above the average analyst 12-month target price of $8.92, changing hands for $8.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AxoGen, Inc. Announces Commercial Release And First Clinical Implant Of Avive™ Soft Tissue Membrane

AxoGen, Inc. Announces Commercial Release And First Clinical Implant Of Avive™ Soft Tissue Membrane

Expanded Nerve Product Portfolio and Other Business Updates to be Discussed Today at AxoGen's Analyst & Investor Event

AXGN Crosses Above Average Analyst Target

AXGN Crosses Above Average Analyst Target

In recent trading, shares of AxoGen Inc have crossed above the average analyst 12-month target price of $8.25, changing hands for $8.55/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AxoGen, Inc. Reports Financial Results For Third Quarter 2016

AxoGen, Inc. Reports Financial Results For Third Quarter 2016

Record revenues of $11.2 million, continued growth in accounts, and increased presence of nerve repair at key medical meetings    

AxoGen, Inc. Announces The Refinancing Of Its Debt Facility

AxoGen, Inc. Announces The Refinancing Of Its Debt Facility

New Agreement Will Replace Existing $25 million Term Loan and Revenue Interest Royalty Agreement, and Reduce Annual Interest Costs by at Least $1.5 Million